Myoglobin(1) (1)

Myoglobin

  • Normal Range: 0-85 ng/ml

  • Used in the early evaluation of suspected myocardial infarction (MI).

  • Diagnosis of disease or injury in skeletal muscle; myoglobin is an oxygen-binding protein in cardiac and skeletal muscle.

  • Elevated levels are due to trauma, inflammation or ischemic changes in non-cardiac skeletal muscles; can reach high levels in sudden or severe muscle injury.

  • Excretion & Toxicity: Myoglobin is excreted in urine and is nephrotoxic.

  • Increased Levels:

    • Myocardial infarction

    • Skeletal muscle inflammation

    • Malignant hyperthermia

    • Muscular dystrophy

    • Skeletal muscle ischemia or trauma

    • Rhabdomyolysis

    • Seizures

  • Decreased Levels: Polymyositis

Prostate-specific Antigen (PSA)

  • Normal Range: <4 ng/ml

  • Used for early detection screening of prostatic cancer; nearly 90% of significant cancers detected with rectal exams.

  • Also used to monitor disease post-treatment.

  • PSA is a glycoprotein, normally found in prostatic epithelial cell cytoplasm; levels rise in prostatic cancer.

  • Increased Levels:

    • Prostate cancer

    • Benign prostatic hyperplasia (BPH)

    • Prostatitis

CA 19-9

  • Normal Range: 37 U/ml

  • Tumor marker for pancreatic or hepatobiliary cancer; used for diagnosis, treatment response evaluation, and monitoring.

  • CA 19-9 is a carbohydrate cell-surface antigen found on cancer cell surfaces.

  • Elevated levels support the diagnosis of pancreatic cancer when a pancreatic mass or biliary obstruction is present.

  • Increased Levels:

    • Pancreatic carcinoma

    • Hepatobiliary carcinoma

    • Pancreatitis

    • Cholecystitis

    • Cirrhosis

    • Gastric cancer

    • Colorectal cancer

    • Gallstones

    • Lung cancer

CA 125

  • Normal Range: 0-35 U/ml

  • Used in detection of ovarian cancer; also to determine disease extent & monitor treatment response.

  • High sensitivity and specificity for ovarian cancer; elevated in over 80% of cases.

  • It aids diagnosis, but is not solely diagnostic for ovarian cancer.

  • Increased Levels:

    • Ovarian cancer

    • Pancreatic cancer

    • Colon cancer

    • Lung cancer

    • Peritoneal carcinomatosis

    • Non-ovarian female genital tract cancer

    • Breast cancer

    • Lymphoma

Prothrombin Time (PT)

  • Normal Findings: 11.0-12.5 seconds

  • Full anticoagulant therapy: > 1.5-2.0 times control value; critical values: > 20 seconds.

  • Evaluates adequacy of the extrinsic system and common pathway in the clotting mechanism.

  • Increased Levels:

    • Liver disease

    • Hereditary factor deficiencies

    • Vitamin K deficiency

    • Bile duct obstruction

    • Coumadin ingestion

    • Disseminated intravascular coagulation (DIC)

    • Massive blood transfusion

    • Salicylate intoxication

Partial Thromboplastin Time, Activated (APTT)

  • Normal Findings: 30-40 seconds

  • Patients on anticoagulant therapy: 1.5-2.5 times control value.

  • Assesses intrinsic system and common pathway of clot formation; monitors heparin therapy.

  • Drugs that May Prolong APTT:

    • Antihistamines

    • Ascorbic acid

    • Chlorpromazine

    • Heparin

    • Salicylates

  • Increased Levels:

    • Congenital clotting factor deficiencies (hemophilia, hypofibrinogenemia)

    • Cirrhosis of the liver

    • Vitamin K deficiency

    • Disseminated intravascular coagulation (DIC)

    • Heparin or Coumadin administration

  • Decreased Levels: Early stages of DIC, extensive cancer.